Brought to you by the team at:
Dive into this whitepaper and learn about:
- The limitations of current hybridoma and single B cell screening techniques
- Why traditional discovery workflows are inefficient and prone to overlooking functional leads
- How function-focused approaches improve the selection of functionally relevant candidates
- How the Lightcast instrument enables single-cell functional screening with superior hit identification
More about this whitepaper:
The antibody discovery landscape is at a turning point. As the demand for more effective and targeted therapeutics grows to tackle challenging targets, traditional methods—focused on binding rather than function—are no longer sufficient. This white paper explores how a shift to function-focused screening, enabled by Lightcast’s single-cell analysis platform, can dramatically improve hit quality and streamline workflows. From improving lead selection to overcoming challenges in ADC development, this white paper is essential reading for anyone looking to modernise their discovery pipeline.
